HB 429 DE
AN ACT TO AMEND TITLE 18 OF THE DELAWARE CODE RELATING TO THE STEP THERAPY EXCEPTION PROCESS.
A state bill is a proposed law in a state legislature — separate from the U.S. Congress. Learn more →
Summary
Delaware HB 429 modernizes the state's step therapy exception process by adding biologics and biosimilars to the list of treatment options covered under the exception process. The bill adds an exclusion to step therapy protocol exceptions for interchangeable biologics and biosimilars, updating law that was passed before biosimilars were widely available. Biosimilars function as cost-effective alternatives to brand-name biologic medications, similar to how generic drugs provide alternatives to traditional medications.
AI-generated plain-language summary of the bill (from the OpenStates abstract — no full text available yet) — neutral, and may be imperfect.
Official abstract
This Act modernizes Delaware law by adding modern medical treatment options biologics or biosimilars to the step therapy exception process. The current law was passed before biosimilars were widely available. Biosimilars are to biologics what generic drugs are to traditional drugs once their exclusivity expires. This revision adds an exclusion to step therapy protocol exceptions for interchangeable biologics and biosimilars.
Sponsors (13)
- Melissa Minor-Brown Democratic · primary
- Marie Pinkney Democratic · primary
- Russell Huxtable Democratic · primary
- Ray Seigfried Democratic · primary
- Eric Morrison Democratic · primary
- Bryant L. Richardson Republican · primary
- Kerri Evelyn Harris Democratic · primary
- Stell Parker Selby · primary
- William J. Carson Democratic · primary
- Spiros Mantzavinos Democratic · primary
- Melanie Ross Levin Democratic · primary
- Claire Snyder-Hall Democratic · primary
- Nicole Poore Democratic · primary
Action history (7)
- May 19, 2026 Introduced and Assigned to Economic Development/Banking/Insurance & Commerce Committee in House · lower
- Jun 9, 2026 Reported Out of Committee (Economic Development/Banking/Insurance & Commerce) in House with 3 Favorable, 6 On Its Merits · lower
- Jun 11, 2026 Passed By House. Votes: 38 YES 1 NO 2 ABSENT · lower
- Jun 11, 2026 Assigned to Banking, Business, Insurance & Technology Committee in Senate · upper
- Jun 23, 2026 Reported Out of Committee (Banking, Business, Insurance & Technology) in Senate with 5 On Its Merits · upper
- Jun 24, 2026 Passed By Senate. Votes: 21 YES · upper
- Jul 23, 2026 Signed by Governor · executive
Full text
The full text hasn’t been imported yet. CivicGate fetches it from the state legislature’s published version documents — check now.
Comments
Data from OpenStates. View on OpenStates →
Comments